search
Back to results

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction (Aspirin-BVT)

Primary Purpose

Healthy

Status
Unknown status
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Aspirin ingestion followed by doing a Bleeding Volume Test
Gatorade Placebo followed by Bleeding Volume Test.
Sponsored by
Klein, Jeffrey A., M.D.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Healthy focused on measuring platelet function test, platelets, in vivo test, aspirin, aspirin resistance, aspirin non-responsiveness, in-vivo, To assess the specificity and sensitivity of a novel in-vivo diagnostic test of platelet function, To use this test to define and assess "aspirin resistance"

Eligibility Criteria

18 Years - 89 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Adult male and female
  • Ages 18 to 89 years old

Exclusion Criteria:

  • Any history of HIV, Hepatitis C or presence of a blood-borne infectious disease

Sites / Locations

  • Private practice office
  • Capistrano Surgery Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Patient drinks aspirin in Gatorade.

Gatorade Placebo

Arm Description

Patient drinks Gatorade containing 325 mg aspirin. Bleeding Volume Test is done one hour later.

Patient ingests Gatorade and one hour later a Bleeding Volume Test is performed

Outcomes

Primary Outcome Measures

Sensitivity, Specificity & ROC curve characteristics of the Bleeding Volume Test

Secondary Outcome Measures

Full Information

First Posted
January 12, 2010
Last Updated
July 18, 2015
Sponsor
Klein, Jeffrey A., M.D.
search

1. Study Identification

Unique Protocol Identification Number
NCT01047722
Brief Title
In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction
Acronym
Aspirin-BVT
Official Title
Bleeding Volume Test: A Double-Blind Crossover Randomized Clinical Trial of an In-Vivo On-Line Test for Aspirin Effect and Resistance
Study Type
Interventional

2. Study Status

Record Verification Date
July 2015
Overall Recruitment Status
Unknown status
Study Start Date
January 2010 (undefined)
Primary Completion Date
October 2015 (Anticipated)
Study Completion Date
October 2015 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Klein, Jeffrey A., M.D.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Purpose of the present research project is to study a new in-vivo test for abnormal platelet function and to study the effect of certain drugs on clinical bleeding. This is a randomized clinical trial of a new in-vivo test of platelet function known as the bleeding volume test(BVT)which relies on an on-line measurement system. This trial will assess the sensitivity and specificity of the new BVT by studying the effects of aspirin which is known to affect platelet function in-vivo. This is not a clinical trial of drugs. This is a clinical trial of a novel in-vivo on-line laboratory test. The BVT measures the total volume of blood in the discrete blotches of blood on the blotter paper during the BT test and thus the BVT gleans valuable additional information from the bleeding time test (BTT)procedure. We hypothesize that the BV test will be a more accurate, specific and sensitive test for diagnosing platelet function abnormalities and for detecting a person's bleeding tendency compared to the BTT, and commercially available in-vitro platelet function tests.
Detailed Description
Purpose of the present research project is to study a new in-vivo test for abnormal platelet function and to study the effect of certain drugs on clinical bleeding. This is a randomized clinical trial of a new in-vivo test of platelet function known as the bleeding volume (BV) test which relies on an on-line measurement system. This trial will assess the sensitivity and specificity of the new BV test by studying the effects of aspirin which is known to affect platelet function in-vivo. This is not a clinical trial of drugs. This is a clinical trial of a novel laboratory test. The BV test results will be compared to the results of two commercially available platelet function tests (the VerifyNow test and the PFA-100 test) which requires 10 ml of blood taken from a peripheral vein. The bleeding volume test is an extension of the classic Ivy Bleeding Time Test (BTT). The BTT, an in-vivo test for an abnormal bleeding tendency, involves making a small standardized cut in the skin and measuring the duration of bleeding. We hypothesize that measuring both the volume of blood lost (BV) and the BT will to provide a more useful test. The BV test is expected to provide an improved in-vivo technique for 1) investigating the effects of drugs on platelet function and 2) diagnosing diseases of abnormal platelet function such as von Willebrand disease (vWD), 3) identifying patients who are aspirin-resistant in the sense that they do not benefit from the beneficial effects of aspirin in preventing thromboembolic disease (heart attack and stroke), 4) providing insight into the effects of antithrombotic drugs such as clopidogrel, lidocaine and statins (HMG-CoA reductase inhibitors). The BV test will provide an inexpensive diagnostic test and improve patient care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
platelet function test, platelets, in vivo test, aspirin, aspirin resistance, aspirin non-responsiveness, in-vivo, To assess the specificity and sensitivity of a novel in-vivo diagnostic test of platelet function, To use this test to define and assess "aspirin resistance"

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Patient drinks aspirin in Gatorade.
Arm Type
Active Comparator
Arm Description
Patient drinks Gatorade containing 325 mg aspirin. Bleeding Volume Test is done one hour later.
Arm Title
Gatorade Placebo
Arm Type
Placebo Comparator
Arm Description
Patient ingests Gatorade and one hour later a Bleeding Volume Test is performed
Intervention Type
Drug
Intervention Name(s)
Aspirin ingestion followed by doing a Bleeding Volume Test
Intervention Description
Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
Intervention Type
Procedure
Intervention Name(s)
Gatorade Placebo followed by Bleeding Volume Test.
Intervention Description
Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
Primary Outcome Measure Information:
Title
Sensitivity, Specificity & ROC curve characteristics of the Bleeding Volume Test
Time Frame
one year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
89 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Adult male and female Ages 18 to 89 years old Exclusion Criteria: Any history of HIV, Hepatitis C or presence of a blood-borne infectious disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jeffrey A Klein, MD
Organizational Affiliation
University of Californiia, Riverside
Official's Role
Principal Investigator
Facility Information:
Facility Name
Private practice office
City
Newport Beach
State/Province
California
ZIP/Postal Code
92660
Country
United States
Facility Name
Capistrano Surgery Center
City
San Juan Capistrano
State/Province
California
ZIP/Postal Code
92675
Country
United States

12. IPD Sharing Statement

Learn more about this trial

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction

We'll reach out to this number within 24 hrs